Olumide B. Gbolahan, MBBS, MSc, discusses the key biomarkers oncologists should test for to determine the optimal treatment for patients with colorectal cancer (CRC).
Olumide B. Gbolahan, MBBS, MSc, assistant professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine, discusses the key biomarkers oncologists should test for to determine the optimal treatment for patients with colorectal cancer (CRC).
According to Gbolahan, these biomarkers can be identified with circulating tumor DNA (ctDNA) assays. Aside from mismatch repair protein status, he explains that looking for BRAF, KRAS, and HER2 mutations is important.
0:08 | The biomarkers will fall into two broad categories; the biomarkers that would predict response to treatments, whatever treatment we offer patients, and then also biomarkers that may help us with prognostication.
0:27 | I think that the ctDNA assays are adding information to prognostication. Maybe. We don't know yet. That will be helpful to determine how patients respond to therapy. But I think it's important that as a biomarker for prognosis, everybody should be tested for mismatch repair protein status on their tumors. I think that this is important for not just prognosis. Yes, it's useful for making decisions about genetic counseling bonds, depending on the stage of the disease. For instance, for stage four cancers and more and more even for colorectal cancer as resectable. This is also useful for picking treatment options in terms of chemotherapy versus immunotherapy. So, mismatch repair protein status is a very useful marker in colorectal cancer. And there are other genetic tests or genomic tests that we do that may be helpful that are helpful for prognosis and prediction of response to treatments like BRAF mutation status, KRAS, mutation status and things like that HER2 also do.
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
Examining Breast Cancer Recurrence Detection Methods in a Community Oncology Setting
July 12th 2024In an interview with Targeted Oncology, Ali Duffens, MD, discussed findings from a study which investigated detecting breast cancer recurrence among women treated at Kaiser Permanente Northern California.
Read More